<DOC>
	<DOC>NCT01305148</DOC>
	<brief_summary>The WARFARIN Study is a clinical trial designed to determine if the use of genetic information related to warfarin sensitivity can help create a dose of warfarin that will result in less hospitalizations and deaths related to warfarin.</brief_summary>
	<brief_title>Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>1. Men and women at least 65 years old 2. Beginning warfarin (0 3 doses of warfarin taken at the time of enrollment) for a variety of diseases or conditions that require at least 30 days oral anticoagulation with target INR â‰¥ 2.0 1. Unable to complete the study materials (questionnaires) with or without assistance (for example, those with dementia) 2. A previous genetically determined warfarin dose 3. The treating physician does not agree to use the recommended warfarin dose or feels that the patient should not be enrolled in the study</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>warfarin</keyword>
	<keyword>genetic testing</keyword>
	<keyword>personalized medicine</keyword>
	<keyword>anti-coagulants</keyword>
	<keyword>coumadin</keyword>
</DOC>